{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:44:46Z","timestamp":1789940686833,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is used in the palliative treatment of peritoneal metastasis. The combination of intraperitoneal and systemic chemotherapy seems rational, and the aim of this systematic review was to compare PIPAC directed monotherapy with a bidirectional treatment approach (PIPAC in combination with systemic chemotherapy). Main outcomes were survival and quality of life.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A systematic literature search in Medline, Embase, Cochrane and the \u201cPleura and Peritoneum\u201d was conducted and analyzed according to PRISMA guidelines. Studies in English reporting on bidirectional treatment with PIPAC and systemic chemotherapy and published before April 2019 were included.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Twelve studies with a total of 386 patients were included. None were specifically designed to compare mono- versus bidirectional treatment, but 44% of the patients received bidirectional treatment. This was more frequent in women (non-gynecological cancers) and one-third of the bidirectional treated patients had received no prior chemotherapy. Data from the included studies provided no conclusions regarding survival or quality of life.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Bidirectional treatment with PIPAC and systemic chemotherapy is practised and feasible, and some patients are enrolled having received no prior systemic chemotherapy for their PM.<\/jats:p>\n<jats:p>The difficulty in drawing any conclusions based on this systematic review has highlighted the urgent need to improve and standardize reports on PIPAC directed therapy. We have, therefore, constructed a list of items to be considered when reporting on clinical PIPAC research.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>International Prospective Register of Systematic Reviews, PROSPERO. Registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=90352\">90352<\/jats:ext-link>, March 5, 2018.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-6572-6","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T17:02:50Z","timestamp":1581354170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-3994","authenticated-orcid":false,"given":"Magnus","family":"Ploug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Graversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bau","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"6572_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/bjs.10521","volume":"104","author":"F Grass","year":"2017","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, H\u00fcbner M, et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017;104:669\u201378.","journal-title":"Br J Surg"},{"key":"6572_CR2","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJP, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142:2275\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"key":"6572_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553\u20139.","journal-title":"Ann Surg Oncol"},{"key":"6572_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2:47\u201362.","journal-title":"Pleura Peritoneum."},{"key":"6572_CR5","first-page":"18","volume":"7","author":"MG Neuwirth","year":"2016","unstructured":"Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7:18\u201328.","journal-title":"J Gastrointest Oncol"},{"key":"6572_CR6","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol"},{"key":"6572_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, HWR S, RHM H, et al. Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med"},{"key":"6572_CR8","doi-asserted-by":"publisher","first-page":"175883591877703","DOI":"10.1177\/1758835918777036","volume":"10","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:175883591877703.","journal-title":"Ther Adv Med Oncol"},{"key":"6572_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2:116\u201323.","journal-title":"Ann Gastroenterol Surg"},{"key":"6572_CR10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol"},{"key":"6572_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal Cisplatin and paclitaxel in ovarian Cancer. NEJM. 2006;354:34\u201343.","journal-title":"NEJM."},{"key":"6572_CR12","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"D Alberts","year":"1996","unstructured":"Alberts D, Liu P, Dward HAnnigan EV, Robert O, WiIlliams S, Ames Y, Oung JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. NEJM. 1996;335:1950\u20135.","journal-title":"NEJM."},{"key":"6572_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/annonc\/mdw617","volume":"28","author":"CSEW Schuurhuizen","year":"2017","unstructured":"Schuurhuizen CSEW, Braamse AMJ, Konings IRHM, Sprangers MAG, Ket JCF, Dekker J, et al. Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. Ann Oncol. 2017;28:478\u201386.","journal-title":"Ann Oncol"},{"issue":"6","key":"6572_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, Bao Y, Shah MA, Elizabeth Paulk M, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778\u201384.","journal-title":"JAMA Oncol"},{"key":"6572_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"LE Schnipper","year":"2012","unstructured":"Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1715\u201324.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6572_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42:1123\u201331.","journal-title":"Eur J Surg Oncol"},{"key":"6572_CR17","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1245\/s10434-017-6033-x","volume":"24","author":"F Le Roy","year":"2017","unstructured":"Le Roy F, Gelli M, Hollebecque A, Honor\u00e9 C, Boige V, Dartigues P, et al. Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24:3640\u20136.","journal-title":"Ann Surg Oncol"},{"key":"6572_CR18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1245\/s10434-016-5665-6","volume":"24","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Huitema ADR, Burger JWA, Brandt-Kerkhof ARM, Van Den Heuvel SF, Verwaal VJ. Standard clinical protocol for bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC): systemic leucovorin, 5-fluorouracil, and heated intraperitoneal oxaliplatin in a chloride-containing carrier solution. Ann Surg Oncol. 2017;24:990\u20137.","journal-title":"Ann Surg Oncol"},{"key":"6572_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/890450","volume":"2012","author":"Lana Bijelic","year":"2012","unstructured":"Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012:890450. https:\/\/doi.org\/10.1155\/2012\/890450.","journal-title":"Gastroenterology Research and Practice"},{"key":"6572_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s13193-016-0498-0","volume":"7","author":"SJ Valle","year":"2016","unstructured":"Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7:152\u20139.","journal-title":"Indian J Surg Oncol"},{"key":"6572_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"6572_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1\u20131.","journal-title":"Syst Rev"},{"key":"6572_CR23","doi-asserted-by":"crossref","unstructured":"Khomyakov V, Ryabov A, Bolotina L, Ivanov A, Cheremisov V, Kolobaev I, et al. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for treatment of peritoneally disseminated gastric cancer. Ann Oncol. 2016;27 Suppl 2:1\u201385.","DOI":"10.1093\/annonc\/mdw199.166"},{"issue":"3","key":"6572_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","volume":"1","author":"Vladimir Khomyakov","year":"2019","unstructured":"Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159\u201366.","journal-title":"Pleura and Peritoneum"},{"key":"6572_CR25","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.ejso.2016.06.243","volume":"42","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach for peritoneal carcinomatosis. Eur J Surg Oncol. 2016;42:S155.","journal-title":"Eur J Surg Oncol"},{"key":"6572_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.","journal-title":"World J Surg Oncol"},{"key":"6572_CR27","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","volume":"43","author":"M Alyami","year":"2017","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178\u201383.","journal-title":"Eur J Surg Oncol"},{"key":"6572_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/codi.13130","volume":"18","author":"C Demtroder","year":"2016","unstructured":"Demtroder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond M-AA, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016;18:364\u201371.","journal-title":"Color Dis"},{"key":"6572_CR29","first-page":"373","volume":"38","author":"TA Falkenstein","year":"2018","unstructured":"Falkenstein TA, Gotze TO, Ouaissi M, Tempfer CB, Giger-Pabst U, Demtroder C, et al. First clinical data of pressurized Intraperitoneal aerosol chemotherapy (PIPAC) as salvage therapy for peritoneal metastatic biliary tract cancer. Anticancer Res. 2018;38:373\u20138.","journal-title":"Anticancer Res"},{"key":"6572_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-017-9849-7","volume":"34","author":"M Graversen","year":"2017","unstructured":"Graversen M, Detlefsen SS, Bjerregaard JK, Pfeiffer P, Mortensen MB. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Clin Exp Metastasis. 2017;34:309\u201314.","journal-title":"Clin Exp Metastasis"},{"key":"6572_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2017.28.e80","volume":"28","author":"Z Hilal","year":"2017","unstructured":"Hilal Z, Rezniczek GAGA, Klenke R, Dogan A, Tempfer CB, et al. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: A longitudinal analysis. J Gynecol Oncol. 2017;28:1\u201310.","journal-title":"J Gynecol Oncol"},{"key":"6572_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0186709","volume":"12","author":"T Khosrawipour","year":"2017","unstructured":"Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized intra peritoneal aerosol chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One. 2017;12:1\u201311.","journal-title":"PLoS One"},{"key":"6572_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond M-AA. Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) with low-dose Cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20:367\u201373.","journal-title":"J Gastrointest Surg"},{"key":"6572_CR34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/pp-2016-0005","volume":"1","author":"M Reymond","year":"2016","unstructured":"Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C. Electrostatic precipitation pressurized IntraPeritoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum. 2016;1:109\u201316.","journal-title":"Pleura Peritoneum."},{"key":"6572_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4596176","volume":"4596176","author":"H Teixeira Farinha","year":"2017","unstructured":"Teixeira Farinha H, Grass F, Kefleyesus A, Achtari C, Romain B, Montemurro M, et al. Impact of pressurized Intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract. 2017;4596176:1\u201310.","journal-title":"Gastroenterol Res Pract"},{"key":"6572_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ejso.2017.03.019","volume":"43","author":"M Hubner","year":"2017","unstructured":"Hubner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N, et al. Pressurized IntraPeritoneal aerosol chemotherapy - practical aspects. Eur J Surg Oncol. 2017;43:1102\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"6572_CR37","doi-asserted-by":"publisher","unstructured":"Oliver Goetze T, Al-Batran S-E, Pabst U, Reymond M, Tempfer C, Bechstein WO, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo na\u00efve upper gi-adenocarcinomas with peritoneal seeding \u2013 a phase II\/III trial of the AIO\/CAOGI\/ACO. Pleura Peritoneum. 2018. https:\/\/doi.org\/10.1515\/pp-2018-0113.","DOI":"10.1515\/pp-2018-0113"},{"key":"6572_CR38","doi-asserted-by":"publisher","unstructured":"Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: pressurized IntraPeritoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018. https:\/\/doi.org\/10.1515\/pp-2018-0116.","DOI":"10.1515\/pp-2018-0116"},{"key":"6572_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"6572_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00268-015-3366-0","volume":"40","author":"K Lehmann","year":"2016","unstructured":"Lehmann K, Eshmuminov D, Slankamenac K, Kranzb\u00fchler B, Clavien P-A, Vonlanthen R, et al. Where oncologic and surgical complication scoring systems collide: time for a new consensus for CRS\/HIPEC. World J Surg. 2016;40:1075\u201381.","journal-title":"World J Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6572-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:22:53Z","timestamp":1612833773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6572-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6572"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6572-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}